Based on the key indicators related to Arcutis Biotherapeutics' liquidity, profitability, solvency, and operating efficiency, Arcutis Biotherapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Arcutis Biotherapeutics' Property Plant And Equipment Net is comparatively stable compared to the past year. Net Receivables is likely to gain to about 27.1 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 23.4 M in 2024. Key indicators impacting Arcutis Biotherapeutics' financial strength include:
Investors should never underestimate Arcutis Biotherapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Arcutis Biotherapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Arcutis Biotherapeutics.
Net Income
(249.03 Million)
Arcutis
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Days Of Inventory Outstanding
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Investments
Change In Cash
Net Borrowings
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Long Term Debt
Cash And Short Term Investments
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Surpluse
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Total Current Assets
Net Working Capital
Other Liab
Capital Stock
Non Current Liabilities Other
Short Long Term Debt Total
Property Plant And Equipment Net
Net Receivables
Capital Lease Obligations
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Short Term Debt
Common Stock
Property Plant Equipment
Inventory
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Depreciation And Amortization
Income Tax Expense
Gross Profit
Cost Of Revenue
Probability Of Bankruptcy
Understanding current and past Arcutis Biotherapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Arcutis Biotherapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Arcutis Biotherapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Arcutis Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arcutis Biotherapeutics. Check Arcutis Biotherapeutics' Beneish M Score to see the likelihood of Arcutis Biotherapeutics' management manipulating its earnings.
Arcutis Biotherapeutics Stock Summary
Arcutis Biotherapeutics competes with Terns Pharmaceuticals, Amylyx Pharmaceuticals, Acumen Pharmaceuticals, Inozyme Pharma, and X4 Pharmaceuticals. Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. Arcutis Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 147 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Arcutis Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Arcutis Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arcutis Biotherapeutics competition to find correlations between indicators driving Arcutis Biotherapeutics's intrinsic value. More Info.
Arcutis Biotherapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Arcutis Biotherapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Arcutis Biotherapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Arcutis Biotherapeutics Systematic Risk
Arcutis Biotherapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Arcutis Biotherapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Arcutis Biotherapeutics correlated with the market. If Beta is less than 0 Arcutis Biotherapeutics generally moves in the opposite direction as compared to the market. If Arcutis Biotherapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Arcutis Biotherapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Arcutis Biotherapeutics is generally in the same direction as the market. If Beta > 1 Arcutis Biotherapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Arcutis Biotherapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Arcutis Biotherapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Arcutis Biotherapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.0254
At this time, Arcutis Biotherapeutics' Price Earnings To Growth Ratio is comparatively stable compared to the past year.
Arcutis Biotherapeutics November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Arcutis Biotherapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Arcutis Biotherapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Arcutis Biotherapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Arcutis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Arcutis Biotherapeutics's daily price indicators and compare them against related drivers.
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.